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Synthesis of diversely functionalised 2,2-disubstituted
oxetanes: fragment motifs in new chemical space†
Owen A. Davis, Rosemary A. Croft and James A. Bull*
Di-, tri- and tetra-substituted oxetane derivatives with combinations
of ester, amide, nitrile, aryl, sulfone and phosphonate substituents
are prepared as fragments or building blocks for drug discovery. The
synthesis of these novel oxetane functional groups, in new chemical
space, is achieved via rhodium-catalysed O–H insertion and C–C
bond forming cyclisation.
Recent years has seen considerable enthusiasm for exploring new
chemical motifs in medicinal chemistry that enter unexplored
chemical and intellectual property (IP) space.1,2 Oxetanes motifs
have gained significant traction as desirable modules for drug
discovery.3 Carreira, Rogers-Evans, Mu¨ller and co-workers demon-
strated that 3,3-disubstituted oxetanes constitute polar replace-
ments for gem-dimethyl groups, and often aﬀord improved
solubility and physicochemical properties.4 Subsequently,
oxetane motifs have been adopted widely in medicinal chemistry
programs.5,6 3-Substituted oxetane motifs have been examined
in particular, exploiting oxetan-3-one3,4 and 3-iodooxetane7 as
building blocks. New spirocycles,8 peptidomimetics9 and other
oxetane analogues of important compounds have been prepared
(e.g. Fig. 1).6,10
Examples of 2-substituted oxetanes remain less studied; Pfizer
reported a class of 2-oxetanyl containing g-secretase inhibitors
that possessed improved properties relative to tetrahydrofuran
and carbocyclic derivatives.6 However, oxetanes bearing functional
groups on the ring are unexplored, and could provide fascinating
new structural units for use by medicinal chemists. The synthesis
of functionalised oxetanes continues to be a challenge. Cyclisation
by intramolecular Williamson etherification is most common,3
but 2-functionality is often precluded due to unstable oxyanionic
intermediates. Also, epoxide-opening and ring-closure methods
using sulfoxonium ylides are not tolerant of sensitive electro-
philic functionality.11 On the other hand, the photochemical
Paterno–Bu¨chi reaction can introduce functionality from an
alkene component, but is often restricted to very highly sub-
stituted oxetanes, with undesirable properties for medicinal
chemistry.12–14
We have targeted new oxetane derivatives due their small, polar
nature and well-defined 3-D shape.15 We recently reported the
preparation of 2-sulfonyl oxetanes, formed through a novel anionic
C–C bond forming cyclisation (Scheme 1A).16 These fragments
displayed good pH stability, and stability to liver microsomes.16b
We have also established an efficient synthesis of oxetane 2,2-
dicarboxylates involving O–H insertion using diazomalonates, and
C–C bond forming cyclisation (Scheme 1B).17
Here we report the synthesis of unusual oxetane motifs
bearing medicinally relevant functional groups directly on the
Fig. 1 Biologically active oxetane-containing compounds.
Scheme 1 Synthesis of oxetanes through anionic C–C bond forming
cyclisation.
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ring (Scheme 1C). Diversely functionalised oxetanes in new
chemical space are prepared in a facile manner from function-
alised diazo compounds by O–H insertion and C–C bond
forming cyclisation. These simple but highly functionalised
motifs provide interesting shape and physicochemical pro-
perties for fragments or building blocks for drug discovery that
cannot be prepared by other methods.
Targeting 2,2-difunctionalised oxetanes, our investigations
initially focused on a range of unsymmetrical acceptor–acceptor
diazo compounds, with which to examine O–H insertion with
2-bromoethanol (Scheme 1C and Table 1).18,19 A series of diazo
compounds 1a–g bearing amide, sulfone, phosphonate, and
nitrile groups were prepared from the methylene precursors
using TsN3 or TfN3.
18,20,21 We first examined amide–ester diazo
1a (entry 1). Pleasingly, using catalytic Rh2(OAc)4 (0.5 mol%) in
benzene at 80 1C successfully mediated O–H insertion of the
carbene derived from diazo 1a into 2-bromoethanol in 75% yield.
Cyclisation was then eﬀected by treatment of 2a with NaH
(1.2 equiv., 0 1C, 1 h, then 25 1C, 1 h) to aﬀord 2-amido-2-ester-
oxetane 3a in excellent yield forming the C(2)–C(3) bond. Using
Weinreb amide 1b (entry 2), a slightly reduced yield was obtained
for the O–H insertion (51%), but an excellent yield was obtained
on cyclisation of 2b to oxetane 3b. Sulfone–ester diazo 1c
smoothly underwent O–H insertion, followed by cyclisation in
just 1 h at 0 1C to provide a new type of sulfonyl oxetane
(entry 3).16 Phosphonate–ester diazo 1d proceeded similarly,
to yield the first example of a 2-oxetanyl phosphonate, 3d.22
Interestingly, the use of nitrile–ester diazo 1e led to side
reactions under the conditions for O–H insertion, with the
carbenoid undergoing competitive insertion into the benzene
solvent (1.2 : 1–2.4 : 1 O–H insertion : p-insertion). To prevent
this unwanted side product, the reaction was performed in
CH2Cl2 (25 1C, 17 h), and bromide 2e was isolated in 85% yield
(entry 5). Cyclisation at 0 1C afforded nitrile oxetane 3e after 1 h.
The sequence was also successful on a larger scale affording
41.5 g of oxetane 3e in excellent yield (entry 6). Mixed nitrile–
amide and phosphonate–amide diazo compounds were also
successful under the same conditions, providing oxetanes
3f and 3g respectively (entries 7 and 8). The wide variety of
substituted oxetanes that can be readily accessed demonstrates
the versatility of this approach.
Substituted bromohydrins were then investigated to form
tri- and tetrasubstituted oxetane derivatives (Table 2). The
reaction sequence successfully formed oxetanes with 4-alkyl
(5a) and 4-aryl substituents (5b–e) in good yields using similar
reaction conditions. The additional substituent had little influence
on the O–H insertion step. However, elevated temperature and
increased reaction times were required for cyclisation of all sub-
stituted examples, requiring 16 h at 25 1C for complete conversion.
For oxetanes 5a and 5b, aB1 : 1 mixture of diastereoisomers
was obtained due to the sterically similar ester–sulfone or
ester–phosphonate groups.23 Diazo compounds with a less
sterically demanding nitrile group (1e, 1h, 1i) gave increased
diastereoselectivity (up to 3 : 1 dr). The incorporation of a 3-Ph
group gave the 2,2,3-substituted derivative 5f (dr = 56 : 44).
2,2,4,4-Tetrasubstituted oxetane 5g was prepared from the
commercially available chlorohydrin (1-chloro-2-methyl-2-propanol)
Table 1 Scope of 2,2-disubstituted oxetanes varying diazo 1a–g
Entry E1 E2 Yield 2a (%) Yield 3b (%) Oxetane 3
1 CO2Et a 75 93
c
2 CO2Et b 51 96
c
3 SO2Ph CO2Et c 92 87
d
4 PO(OEt)2 CO2Et d 77
e 70d
5 CN CO2Bn e 85
f 88d
6 93 f,g 93d,h
7 CN f 67i 87d
8 PO(OEt)2 g 84 72
d
a O–H insertion: 1 (1.1 equiv.), 2-bromoethanol (1.0–2.0 mmol),
Rh2(OAc)4 (0.5 mol%), PhH, 0.1 M, 80 1C.
b Cyclisation: 2 (0.3–0.6 mmol),
NaH (1.2 equiv.), DMF, 0.025 M. c 0 1C for 1 h; then 25 1C for 1 h. d 0 1C
for 1 h. e 1.5 equiv. diazo 1d. f Run in CH2Cl2, 0.1 M at 25 1C for 17 h.
g 10 mmol scale. h 8 mmol scale. i 1.2 equiv. diazo 1f.
Table 2 Preparation of 2,2,4-, 2,2,3-tri- and 2,2,4,4-tetrasubstituted oxetanes
Conditions: (i) O–H insertion: 1 (1.1 equiv.), b-bromohydrin (0.5–1.3mmol),
Rh2(OAc)4 (0.5 mol%), PhH, 0.1 M, 80 1C. (ii) Cyclisation: 4 (0.3–0.5 mmol),
NaH (1.2 equiv.), DMF, 0.025 M, 25 1C, 16 h. a dr determined by
1H NMR of crude reaction mixture. b b-Chlorohydrin used. c Oxetane
isomers separated by silica chromatography. d 1.5 equiv. diazo. e Run
in CH2Cl2, 0.1 M at 25 1C for 17 h.
f 1.2 equiv. diazo. g Major diastereo-






















































































This journal is©The Royal Society of Chemistry 2015 Chem. Commun.
in moderate yields. The synthesis of novel fused bicyclic oxetane
scaffold 5h started by treating N-Boc-3-pyrroline with NBS and
H2O to provide 3-bromo-4-hydroxy-pyrrolidine, which gave ether
4h on O–H insertion. Cyclisation then afforded the bicyclic
oxetane 5h as a 83 : 17 mixture of separable diastereoisomers in
95% combined yield.21,23
Next we examined aryl–ester (donor–acceptor) diazo com-
pounds,24 to generate 2-aryl-oxetane-2-carboxylates (Table 3).
Such aryl-substituted heterocycles offer attractive features
for fragment screening and are little studied in medicinal
chemistry.25 To our delight, the O–H insertion conditions were
effective for the phenyl–ester diazo 6a with an excellent 86%
yield using reduced Rh2(OAc)4 loading (0.25 mol%, entry 1).
The O–H insertion was successful across varied aryl groups
(entries 3–8), including the chloropyridyl diazo 6f. However,
using the NaH in DMF conditions for cyclisation gave variable
yields and oxetane 8a and bromide 7a proved inseparable.
Alternative bases and conditions were examined,21 and the
use of LiHMDS (1.4 equiv.) in THF was found to give quantita-
tive conversion to oxetane 8a with a 93% isolated yield (entry 1).
This reaction sequence was similarly successful on a larger
scale (entry 2). The modified cyclisation conditions worked well
for substituted aryl derivatives including halogenated (entries 4
and 5), and pyridyl derivatives (entry 8). However, the electron
rich p-methoxy phenyl substrate (entry 6) led to low conversion
and isolated yield. Using a larger excess of LiHMDS (2 equiv.)
gave an improved yield of 41% (entry 7). The cyclisation condi-
tions were also effective for aryl–amide ether 7g (entry 9). This
approach provided direct access to compounds that conform
well to fragment guidelines for fragment screening.21
As a more divergent approach to similar compounds, hydro-
lysis of ester oxetane 8a was examined (Scheme 2a). Using NaOH
aﬀorded sodium salt 9 as an attractive oxetane containing build-
ing block. Amide coupling with morpholine, directly from the
salt,26 gave amide 10 in a good yield over two steps. Finally,
we prepared additional 2-nitrile oxetane derivatives. The nitrile
group is receiving considerable attention in drug discovery,27,28
being metabolically robust and a strong hydrogen bond acceptor.
Therefore, we considered that the combination with an oxetane
motif could present a fascinating structure for medicinal
chemistry.13,29 From nitrile–oxetane benzyl ester 3e, ester hydro-
lysis was best achieved using LiOH to afford lithium salt 11
(Scheme 2b). Amide bond formation gave nitrile amide oxetanes
12 and 13 in 30–35% yields over 2 steps. Importantly, treatment
of oxetane 3f with TFA promoted Boc deprotection, 14, without
other degradation, providing encouraging preliminary informa-
tion on acid stability (Scheme 2c; 10 equiv. TFA, 22 h).
In summary, we have developed a versatile strategy to
prepare diversely functionalised oxetane derivatives, involving
O–H insertion and C–C bond forming cyclisation. A wide variety
of functional groups have been introduced on the oxetane ring,
accessing new chemical space. We believe these oxetane motifs
will provide interesting new structural elements for medicinal
chemistry programs as well as synthesis. Efforts towards enantio-
selective synthesis and studies on the stability and medicinal
chemistry properties of the new oxetane derivatives will be
reported in due course. We gratefully acknowledge EPSRC
Table 3 Scope of 2-aryl-oxetane 2-carboxylates
Entry Ar E Yield 7a (%) Yield 8b (%) Oxetane 8
1 Ph CO2Et a 86 93
2 80c 76d
3 Ph CO2iPr b 87
e 72
4 3-ClPh CO2Et c 69 97
5 4-CF3Ph CO2Et d 64 77
6 4-MeOPh CO2Et e 86 22
7 41f
8 CO2Et f 54 76
9 3-ClPh g 73 90
a O–H insertion: 6 (1.1–1.5 equiv.), 2-bromoethanol (0.4–2.0 mmol),
Rh2(OAc)4 (0.25 mol%), PhH, 0.1 M, 80 1C.
b Cyclisation: 7 (0.3–0.5 mmol),
LiHMDS (1.4 equiv.), THF, 0.025 M, 0 1C, 1 h. c Reaction on 7.5 mmol
scale. d Reaction on 5.0 mmol scale. e 0.5 mol% Rh2(OAc)4.
f 2.0 equiv.
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